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Summary
OBJECTIVES: Atrial fibrillation is a major risk factor for
ischemic stroke and anticoagulation therapy is indicated to
reduce risk. Dabigatran is a new oral anticoagulant that
does not require INR monitoring. This study evaluated the
cost-effectiveness of dabigatran versus vitamin K antagon-
ists for stroke prevention in atrial fibrillation in Switzer-
land.
METHODS: A Markov model simulating the course of
treatment and occurrence of clinical events in two treat-
ment arms over the lifetime of patients was adapted to the
Swiss context. The adaptation included the cost of antico-
agulation therapy and clinical events in Switzerland. The
cost of inpatient care was estimated on data of all inpatient
hospital stays in 2008. The calculation of outpatient care
costs was based on peer reviewed studies, expert interviews
and local tariffs.
RESULTS: Patients treated with dabigatran had a higher
life expectancy and experienced more quality adjusted life
years (QALY) while incurring higher costs than patients
treated with vitamin K antagonists. The estimated incre-
mental cost-effectiveness ratio (ICER) was CHF 25,108.‒
per QALY with 110 mg and CHF 9,702 per QALY with
150 mg of dabigatran. A sequential dosage scheme, in
which 150 mg are administered up to the age of 80 years
and 110 mg thereafter, resulted in an ICER of CHF 10,215
per QALY. A sensitivity analysis confirmed that these res-
ults are robust.
CONCLUSIONS: Dabigatran can be considered cost-ef-
fective in comparison with vitamin K antagonists in the
Swiss context. The higher drug cost of dabigatran is com-
pensated by savings in INR monitoring, lower cost of clin-
ical events and QALY-gains.
Key words: dabigatran; warfarin; marcoumar; oral
anticoagulation; atrial fibrillation; stroke prevention;
vitamin K antagonist; VKA; cost; cost-effectiveness;
QALY; ICER; Switzerland
Introduction
Atrial fibrillation is the most common sustained cardiac ar-
rhythmia in the general population and its prevalence in-
creases with age [3, 4]. Atrial fibrillation is a major risk
factor for ischemic stroke and strokes due to atrial fibril-
lation are more severe than other types of IS [5, 6]. Thus
oral anticoagulation therapy is strongly indicated for the re-
duction of stroke risk. The current standard of care in or-
al anticoagulation therapy is vitamin K antagonists (VKA),
which require constant INR monitoring [7].
Dabigatran is an oral direct thrombin inhibitor that is taken
in a fixed dose twice daily (BID). It does not require INR
monitoring and does not interact with food [8]. Dabigatran
has proven to be very effective in preventing IS while
avoiding haemorrhagic events [9, 10]. Although dabigatran
can save INR monitoring costs, drug costs are higher than
with VKA.
Abbreviations
AF: atrial fibrillation
AMI: acute myocardial infarction
ASA: acetylsalicylic acid
BID: twice a day
CHADS: stroke risk prediction rule (congestive heart failure,
hypertension, age, diabetes, prior stroke)
DRG: diagnosis related groups
ECH: extracranial haemorrhage
GP: general practitioner
HS: haemorrhagic stroke
ICER: incremental cost-effectiveness ratio: Difference in total cost
between two therapy options divided by the difference in QALY.
Expresses the additional cost per QALY gained by choosing the
more effective therapy option.
IH: intracranial haemorrhage
INR: international normalized ratio
IS: ischemic stroke
MB: minor bleed
MedStat: Swiss Medical Statistics of Hospitals: This dataset
contains information on all hospitalizations in Swiss hospitals.
Patients are tagged with the same ID during all inpatient stays.
PSA: probabilistic sensitivity analysis
QALY: quality adjusted life year: The product of quality of life and life
years. One life year at 50% quality of life corresponds to 0.5 QALY.
RR: relative risk
SA: sensitivity analysis
SE: systemic embolism
TIA: transient ischemic attack
TTR: time in therapeutic INR range
VKA: vitamin K antagonist
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Cost-effectiveness analysis is needed to determine whether
the preventive effects and the savings of INR monitoring
costs are worth the higher price of dabigatran. Studies in
other countries have shown that dabigatran is cost-effective
among AF patients with a medium to high risk of stroke
when compared to a well-adjusted VKA [2, 11–14] . As
these results are dependent on the local standard of care,
local prices and peculiarities of the local health care sys-
tem, they cannot be transferred to other countries. This may
be particularly important in the context of the Swiss health
care system with its comparably high per-capita health care
expenditures.
In this study we assessed the cost-effectiveness of dabigat-
ran versus VKA for stroke prevention in AF in Switzer-
land.
Model
A cost-effectiveness model originally developed by
Sorensen et al. [1, 2] was adapted to the Swiss context. The
model has a Markov structure and simulates the occurrence
of clinical events in 3 month cycles over the remaining life-
time of patients. Clinical events include IS, systemic em-
Figure 1
Simplified representation of Markov model.
Health states are modelled in 3-month cycles in which a patient
may experience no event, a clinical event, or death. All clinical
events induce one-time treatment costs and a temporary loss of
quality of life. IS, HS, and ICH may lead to permanent disability
(moderate or total) causing long-term follow-up costs and a
permanent loss of quality of life. Disability levels can only get worse
and never improve.
After a haemorrhagic event, 50% of the patients are assumed to
discontinue treatment. Without any event, the time until treatment
discontinuation is modelled by a Weibull hazard function based on
data from the RE-LY trial. After treatment discontinuation, 70% of
patients on dabigatran and 78% of patients on VKA are assumed to
use ASA as a second line treatment.
AMI = acute myocardial infarction; ECH = extra-cranial
haemorrhage; HS = hemorrhagic stroke; ICH = intracranial
haemorrhage, IS = ischemic stroke; MB = minor bleed; SE =
systemic embolism; TIA = transient ischemic attack.
bolism (SE), transient ischemic attack (TIA), intracranial
haemorrhage (IH), haemorrhagic stroke (HS), extra-crani-
al haemorrhage (ECH), minor bleed (MB), acute myocar-
dial infarction (AMI) and death. According to definitions
in the RE-LY trial, HS include intra-cerebral and subarach-
noid haemorrhages, and ICH consists of HS and subdural
haemorrhage [9]. All clinical events induce one-time treat-
ment costs and a temporary loss of quality of life. Some
clinical events (IS, HS and ICH) may also lead to perman-
ent disability causing long-term follow-up costs and a per-
manent loss of quality of life. The disability status of these
patients is categorised as independent, moderately depend-
ent or totally dependent. See figure 1 for a simplified rep-
resentation of the model structure and the publications by
the authors of the model for a detailed description [1, 2].
The model compared two treatment arms; one with dabi-
gatran and the other with VKA as the first line treatment. In
both arms, treatment can be switched to acetylsalicylic acid
(ASA) as a second line treatment or can be discontinued.
While in Anglo-Saxon countries warfarin is considered the
standard VKA, we substituted it with phenprocoumon, the
most common VKA in Switzerland [15, 16]. Warfarin and
phenprocoumon have proven to be equally effective in an-
ticoagulation therapy [17, 18]. The choice of phenprocou-
mon as a comparator therefore only affects daily drug costs
but not the probabilities of clinical events.
The dosage of dabigatran was modelled in three different
scenarios: single dose scenarios with 110 mg or 150 mg
BID and a sequential dose scenario, in which dabigatran is
administered at 150 mg BID until the age of 80 years and at
110 mg BID thereafter. The sequential dose scenario is the
recommended prescribing scheme for the European Union
[19] and Switzerland.
The cost-effectiveness analysis was performed from a pay-
er’s perspective and included all medical costs borne by
health insurance, governmental institutions and patients.
Future costs and QALYs were discounted at a rate of 2%.
This rate represents the real long-term interest rate in
Switzerland [20].
The model delivered the following results for the simulated
patient cohort in the two treatment arms: residual lifetime,
total medical costs, and total QALY experienced in the
model. These results were used to calculate the incremental
cost-effectiveness ratio (ICER) of dabigatran versus VKA.
Univariate sensitivity analysis (SA) covered time in thera-
peutic INR range (TTR), CHADS2 score at model entry,
dabigatran price, INR monitoring costs, and discount rate.
In the probabilistic sensitivity analysis (PSA) model para-
meters were randomly varied within their statistical distri-
butions, based on 95% confidence intervals (CI). Baseline
risks of adverse events in the VKA arm were modelled as
beta distributions due to the special relationship of this dis-
tribution with binomial data. The relative risks for patients
on dabigatran were assumed to be log-normally distributed
as CI of relative risks are estimated on the log scale. Util-
ities were varied within a beta distribution which ensured
a lower bound at zero, and cost inputs were assumed to be
gamma distributed due to the skewed nature often found in
cost data.
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Data
Patient properties were derived from sub-samples of the
RE-LY trial [9, 10]. The average age at model entry was 71
years in the 110 mg and 150 mg scenarios and 69.1 years in
the sequential dose scenario. A total of 63.6% or 65.0% of
patients were males in the separate dose or sequential dose
scenarios. Probabilities of clinical events stemmed from a
mixed treatment comparison of dabigatran versus warfar-
in [21]. In the VKA arm, stroke frequency and severity
also depended on the INR status of patients [22], which
was modelled according to patients in the RE-LY trial [9,
10]. In the base case analysis, the INR was modelled to lie
between 2 and 3 during 64% of study time. Since patients
in clinical trials are usually better managed than in real life
[23, 24], the TTR was subjected to univariate SA. A scen-
ario with well managed Swiss patients using self-checking
devices was also evaluated [24].
Cost of anticoagulation therapy
We calculated the cost of anticoagulation therapy with
dabigatran and VKA in the Swiss context. The daily doses
of dabigatran and phenprocoumon stemmed from clinical
trials and published literature [9, 17, 18]. The number of
INR tests and the associated physician visits were based
on treatment recommendations and a survey of physicians
commissioned by Boehringer Ingelheim [25–27]. Prices of
drugs and services were obtained from publicly available
sources [28–30].
The daily drug cost of dabigatran at retail price was as-
sumed to be CHF 4.00 in all dosage scenarios as this cor-
responds to current retail prices of both dabigatran 110 mg
and 150 mg in Switzerland [31]. The daily dose of phen-
procoumon (Marcoumar®) was assumed to be 2.25 mg [17,
18] at a cost of CHF 0.21 per day [28]. Based on a survey
among general practitioners (GP) [25] and published treat-
ment recommendations [26, 27], we estimated 11.6 INR
tests in the first month of VKA therapy and 1.14 tests per
month thereafter. In the survey, GPs reported an average of
4.6 visits until their patients reached the target band [25].
Niederer et al. [26] recommend a test every 1–2 days un-
til patients reach the target band, and a test every 2–3 days
in the 2–3 weeks thereafter. In the subsequent months, one
test every 3–4 weeks is assumed [26, 27]. As doctors need
to discuss the results of the test, we assumed that there is
a 10-minute consultation at a cost of CHF 23 per test [30].
The duration of the consultation per test was subjected to
univariate SA. On average, INR monitoring costs amount
to CHF 511 per year. We also assumed that one INR test is
done before initiation of dabigatran treatment since a labor-
atory expert and two clinical cardiologists suggested that
some GPs might do an initial INR test in an early phase of
the use of dabigatran although it is not necessary. This is
also in line with the conservative approach we employed in
order to avoid an underestimation of the treatment cost of
dabigatran.
Cost of clinical events and long-term follow-up costs
We calculated the one-time cost of clinical events and long-
term follow-up costs according to the Swiss standard of
care. Event costs in table 1 comprise of inpatient and out-
patient costs in the first 3 months after a clinical event.
Information on services used in inpatient care (acute care,
rehabilitation, nursing home) stemmed from the Swiss
Medical Statistics of Hospitals (MedStat) [32]. In this data-
set, patients who experienced one of the clinical events can
be identified by ICD-10 diagnoses. The MedStat also con-
tains AP-DRG codes which allow the valuation of inpa-
tient stays by AP-DRG cost weights [33]. These inpatient
costs were then corrected with a mark-up of 13.8% since
inpatient health expenditures calculated by AP-DRG cost
weights underestimate the total cost of inpatient care in
comparison to a more comprehensive source of total inpa-
tient care costs [34, 35]. The cost of inpatient rehabilita-
tion was calculated by multiplying the length of stay from
MedStat and CHF 655, which represents the average daily
tariff of three major rehabilitation clinics (Aar Schinznach-
Bad, Reha Rheinfelden and Rehaklinik Bellikon) in 2008
[36]. The cost of inpatient nursing homes was represented
by medical expenditures in the Statistics of Social Medical
Institutions [37] of CHF 42,360 per year.
Outpatient costs in the first 3 months after a clinical event
covered transportation to the hospital, physician visits,
therapies, diagnostic interventions, medication, outpatient
nursing, and outpatient rehabilitation. The cost of an am-
bulance ride to hospital amounts to CHF 1,252 for IS, HS,
and ICH patients and CHF 1,617 for AMI and SE pa-
tients according to sample invoices of two ambulance ser-
vices. The number and frequency of outpatient physician
visits after an inpatient stay (GPs, neurologists, psychi-
atrists), diagnostic interventions (rest electrocardiography,
holter electrocardiography, magnetic resonance imaging,
neuroangiography), laboratory tests (low-density lipopro-
tein, high-density lipoprotein, hematogram I, potassium,
glucosis, creatinine, presence charge), and drugs used (beta
inhibitors, ACE inhibitors, diuretics, AT-2 inhibitors, an-
tispastics, antieptileptics, antidepressants) were modelled
according to a survey of German experts conducted by
Brüggenjürgen et al. [8]. The results of this survey were
adapted to the Swiss context with the support of local
clinical experts. The amounts charged for these services
were obtained from the list of laboratory analyses [29], the
TARMED medical tariff [30], and the list of medical spe-
cialties [28]. The annual cost of outpatient rehabilitation
was estimated as the cost of physiotherapy of CHF 2,167
from Mahler et al. [39]. The annual cost of outpatient nurs-
ing of CHF 2,807 from Mahler et al. [39] was doubled to
account for contributions by local governments [40] and
corrected to reflect 12% inflation in health care from 2003
to 2008 [41].
Event costs and long-term follow-up costs were calculated
separately for independent, moderately dependent or
totally dependent patients, and for fatal events. IS, HS
and ICH patients discharged to go home and labelled as
“healed” in the MedStat [32] were categorised as independ-
ent patients requiring only outpatient medical care after
the initial inpatient stay (physician visits, therapies, dia-
gnostic interventions, medication). Patients not qualified
as “healed” but discharged to go home were identified as
moderately dependent. It was assumed that these patients
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use outpatient nursing, physiotherapy, and outpatient med-
ical care. Patients transferred to nursing homes after in-
patient care were identified as totally dependent patients.
Their follow-up costs correspond to the costs of medical
care in Swiss nursing homes.
Long-term follow-up costs were determined by medical
services which stroke patients use from the fourth month
after an event. Since quantities of services used decrease
steadily after a stroke [38], long- term follow-up costs per
model cycle are an average over the residual lifetime after
a stroke. In the model, the mean age when experiencing a
stroke was 80 years. 80-year-old individuals have a life ex-
pectancy of 87.5 years and therefore incur follow up costs
during 7.5 years. Although stroke patients may have re-
duced long-term survival [42, 43] , this is in line with our
conservative costing approach. Follow-up costs of outpa-
tient care of independent patients amounted to CHF 368
per 3-month cycle, the costs of care for moderately depend-
ent patients amounted to CHF 2,070 per cycle, and costs in
nursing homes for totally dependent patients amounted to
CHF 10,589 per cycle (table 2).
Quality of life
Data on temporary utility decrements during the cycles
with a clinical event (see table 3) came from Sullivan and
colleagues [44]. Since long term consequences of clinic-
al events were modelled by the use of different disability
levels, estimates of quality of life for minor, moderate and
major stroke from Tengs and Lin [45] were used in the
cycles after an IS, HS or ICH.
Table 1: Event costs of clinical events in the first 3 months. Clinical event costs are the direct medical costs in the first 3 months after an event. For SE, TIA, and AMI, they
include the cost of the first year because these events are treated for longer than just 3 months in Switzerland and the model does not allow long-term follow-up costs for
these events. Sources: Swiss medical statistics of hospitals [32], Brüggenjürgen et al. [38], Mahler et al. [39], Swiss medical tariffs [28–30, 32–34, 37].
Direct medical costs [CHF] Share of inpatient care [%]a
Ischemic stroke
Fatal 9,824 97
Independent 21,377 94
Moderately dependent 23,881 90
Totally dependent 29,333 98
Systemic embolism (1st year)
Fatal 30,876 97
Non-fatal 26,078 91
Transient ischemic attack (1st year) 1,408 0
Intracranial haemorrhage
Fatal 8,298 94
Independent 32,818 96
Moderately dependent 36,860 95
Totally dependent 37,872 98
Haemorrhagic stroke
Fatal 8,298 94
Independent 32,818 96
Moderately dependent 36,860 95
Totally dependent 37,872 98
Extra-cranial haemorrhage
Fatal 16,300 95
Non-fatal, non-GI 13,682 97
Non-fatal, GI 13,881 96
Minor bleed 142 0
Acute myocardial infarction (1st year)
Fatal 7,225 96
Non-fatal 26,249 88
a Inpatient care: hospital, inpatient rehabilitation, nursing home.
Table 2: Composition of follow-up costs per 3-month cycle [CHF]. The follow-up costs represent the average resources an individual uses over its average lifetime after a
stroke of 7.5 years. In the Markov model, the average age when experiencing a stroke is 80 years. At this age the residual life expectancy of all patients in the model is 7.5
years. Sources: Brüggenjürgen et al. [38], Mahler et al. [39], Swiss medical tariffs [28–30].
Independent Moderately dependent Totally dependent
Physician visits 100 100
Laboratory tests 43 43
Diagnostic interventions 89 89
Medication 137 137
Physiotherapy 131
Outpatient nursing 1,572
Inpatient nursing home 10,589
Total 368 2,070 10,589
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Results
Effectiveness
Patients on dabigatran lived longer and experienced higher
quality of life than patients treated with VKA. Considering
the 10,000 patients as a whole, dabigatran led to a gain of
1,949 life years in the 110 mg scenario, 2,330 life years in
the 150 mg scenario, and 2,774 life years in the sequen-
tial dose scenario. The number of clinical events which oc-
curred during the time patients spend in the model (table
4 and table 5) was not only a consequence of the risk of
these events, but also of the residual lifetime since addi-
tional clinical events may occur with additional lifetime
gained. As the sequential dose scenario was modelled on a
slightly different sub-population of the RE-LY trial, the es-
timated number of events cannot be compared directly to
the results from the two single dose scenarios.
The largest effect of dabigatran versus VKA lies in the
strong reduction of HS and ICH. Patients in the dabigatran
110 mg scenario experienced more IS and less HS/ICH
than those in the VKA arm. Patients in the dabigatran 150
mg scenario and in the sequential dose scenario experi-
enced less IS and HS/ICH, and particularly less severely
disabling strokes, despite the longer lifetime of patients.
However, in these two scenarios more extracranial bleed-
ings occurred among patients on dabigatran than in the
VKA arms of the respective models.
QALY gains of patients on dabigatran result from longer
lifetime and quality of life gains due to the prevention of
clinical events and their long-term consequences. QALY
gains in the simulated cohort of 10,000 patients in the dabi-
gatran arm amount to 1,848 QALYs (110 mg scenario),
2,433 QALYs (150 mg scenario), and 2,846 QALYs (se-
quential dose scenario) versus patients on VKA (table 6).
Cost-effectiveness
Dabigatran was able to save INR monitoring costs and
reduce the cost of clinical events. However, overall total
medical costs were higher with dabigatran due to higher
drug costs. Total lifetime medical costs per patient in the
dabigatran arm exceeded medical costs in the VKA arm by
CHF 4,639 with dabigatran 110 mg, by CHF 2,361 with
dabigatran 150 mg, and by CHF 2,907 with sequential dose
dabigatran (table 6). The incremental medical cost per life
year spent in the model amounted to CHF 418 with 110 mg,
CHF 212 with 150 mg and CHF 241 in a sequential dosage
scheme.
When incremental costs are compared to QALYs gained,
dabigatran 110 mg yielded an ICER of CHF 25,108 per
QALY, dabigatran 150 mg yields CHF 9,702 per QALY,
and sequential dose dabigatran yields CHF 10,215 per
QALY.
Sensitivity analysis
The robustness of the results was tested by five univariate
SA and a PSA:
SA on TTR: Since anticoagulation therapy is likely to be
better managed in clinical trials than in real practice [23],
the TTR of 64% from the RE-LY trial was replaced by
the 55% of INR values between 2 and 2.9 from the usual
care arm of a Swiss study comparing self-checking devices
with the standard laboratory analysis [46]. Although some
health systems yield even better results than reported in the
RE-LY trial, 55% is an empirically well supported assump-
tion [47]. This real-world INR adjustment led to a signific-
antly lower ICER of dabigatran versus VKA of CHF 6,291
for the 110 mg scenario. The 150 mg and the sequential
scenarios even become cost-saving under simulated real-
world conditions (table 7). We also evaluate a scenario
with a considerably higher TTR. If patients are within tar-
get range during 72% of time, as in a Swiss study on the
use of self-checking devices [24], the ICERs take values
between CHF 15,239 and 38,608. With a median age of 52
years, however, the participants in this study are consider-
ably younger than the model population.
SA on CHADS2 score at model entry: Following Banerjee
et al. [48] we changed the CHADS2 score distribution from
the RE-LY sample to the values of 0, 1 or 2 to 6 for the
whole model population. The results showed only minor
effects on the ICER in the 150 mg and the sequential
scenarios. However, in the 110 mg scenario, the higher
the CHADS2 score, the less cost-effective dabigatran was
versus VKA.
Table 3: Quality of life decrements due to clinical events.
Mean Std. err. Source
3 month dis-utilities per event
Ischemic stroke 0.139 0.011 Sullivan et al. [44]
Systemic embolism 0.120 0.009 Sullivan et al. [44]
Transient ischemic attack 0.103 0.008 Sullivan et al. [44]
Intracranial haemorrhage 0.181 0.014 Sullivan et al. [44]
Haemorrhagic stroke 0.139 0.011 Sullivan et al. [44]
Extra-cranial haemorrhage 0.181 0.014 Sullivan et al. [44]
Minor bleed 0.004 0.001 Sullivan et al. [44]
Acute myocardial infarction 0.125 0.009 Sullivan et al. [44]
Permanent utility levels by disability status
Independent, without strokea 0.81 0.060 Sullivan et al. [44]
Independent, with stroke 0.65 0.048b Tengs and Lin [45]
Moderately dependent 0.46 0.034b Tengs and Lin [44, 45]
Totally dependent 0.30 0.022b Tengs and Lin [45]
a Quality of life of patients with AF from Sullivan et al. [44]; b standard errors of mean utility levels after a stroke are assumed to be same proportion of the mean as without
stroke from Sullivan et al.
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SA on dabigatran price: We evaluated two additional dabi-
gatran pricing scenarios by varying the assumed base price
of the daily dose of CHF 4.00 by ± CHF 1.00. At a daily
cost of CHF 3.00, the ICER decreased by approximately
40% in the 110 mg scenario. 150 mg and sequential dose
dabigatran were estimated to be cost-saving at a daily drug
cost of CHF 3.00. At a daily cost of CHF 5.00, the ICER
of dabigatran 110 mg increases by 60%, and in the 150
mg and sequential dose scenarios, the ICER more than
doubles.
SA on two additional INR monitoring cost scenarios: (1.)
Yearly cost amounted to CHF 175 when only laboratory
analyses but no GP consultations were included and (2.)
to CHF 735 when a consultation of 15 minutes instead of
10 minutes was assumed with each INR test. The ICER
of dabigatran versus VKA increased substantially in the
first scenario (from +55% in the 110 mg to +108% in the
150 mg scenario) and decreased substantially in the second
scenario (from –35% in the 110 mg to –72% in the 150 mg
scenario).
SA on discount rate: Changing the discount rate of 2% in
the base scenario to 0% or 4% only had a modest effect on
the ICER (table 7).
In the PSA risks of clinical events, probability of treatment
discontinuation, mortality risk, disutility as a result of clin-
ical events, and cost parameters were varied randomly in
10,000 model runs. This allowed the estimation of a mean
ICER and a graphical representation of cost-effectiveness
acceptability curves (CEAC) which showed the probabil-
ities with which the ICER lies below a certain threshold
(fig. 2). The mean ICER was CHF 23,300 in the 110 mg
scenario, CHF 14,818 in the 150 mg scenario, and CHF
13,764 in the sequential dose scenario. The ICER in the
110 mg scenario lay below a threshold of CHF 100,000
with a probability of 95.6% and below a threshold of CHF
50,000 with a probability of 84.0%. For the 150 mg scen-
ario and the sequential dose scenario, the corresponding
probabilities were 99.0% and 99.6% (below CHF 100,000)
and 95.8% and 97.7% (below CHF 50,000).
Discussion
Patients treated with dabigatran have a higher life expect-
ancy and experience more QALYs than patients treated
with VKA. The findings from this study showed that dabi-
gatran is able to save on medical costs of adverse events
and INR monitoring costs but incurs higher total medical
costs over the lifetime of patients due to the drug cost of
dabigatran. Despite the longer lifetime of patients on dabi-
gatran, the reduction of the number of events and the re-
duced stroke severity lead to lower clinical event cost and
lower follow up costs (table 6). The largest effect of dabi-
gatran versus VKA lies in the strong reduction of HS and
ICH. The result that incremental QALYs gained are high-
er than incremental life years gained for dabigatran 150mg
and sequential dose dabigatran indicates that the higher ef-
fectiveness of dabigatran in these scenarios mainly stems
from its capability to reduce the severity of IS and not only
from its superiority in preventing fatal events. This is also
in line with the number of events in table 1 and table 2.
A comparison between the 150 mg and the 110 mg dosage
scenarios showed that the 150 mg dose prevents substan-
tially more IS at the disadvantage of a higher number of
TIA, IH and ECH. Total QALY gains, however, were
clearly higher in the 150 mg scenario and incremental costs
are lower due to the higher costs of the prevented IS. The
ICERs of both the 150 mg and the sequential dose scenario
are less than half the size of the ICER of the 110 mg dosage
scheme.
Table 4: Number of events in the 110 mg and 150 mg dosage scenarios. The number of events represents the sum of clinical events of all 10,000 patients over their entire
time in the model. The difference to the number of events in the VKA arm is the result of relative effectiveness and lifetime of patients.
Dabigatran 110 mg Dabigatran 150 mg VKA
Events [n] ∆ to VKA [n] Events [n] ∆ to VKA [n] ∆ to 110 mg [n] Events [n]
Ischemic stroke 3,907 215 3,528 ‒164 ‒379 3,692
Fatal 1,264 22 1,246 4 ‒18 1,242
Independent 1,551 19 1,482 ‒50 ‒69 1,532
Moderate disability 796 126 592 ‒78 ‒204 670
Totally dependent 297 49 209 ‒39 ‒88 248
Systemic embolism 371 39 372 ‒38 1 410
Fatal 1 0 1 0 0 1
Non-fatal 369 39 370 ‒38 1 408
Transient ischemic attack 1,021 178 1,128 ‒71 107 1,199
Intracranial haemorrhage and haemorrhagic stroke 435 ‒551 518 -468 38 986
Fatal 182 ‒285 222 -245 40 467
Independent 44 ‒42 51 ‒35 7 86
Moderate disability 50 ‒48 58 ‒40 8 98
Totally dependent 159 ‒176 186 ‒149 27 335
Extra cranial haemorrhage 3,323 ‒92 3,647 232 326 3,416
Fatal 38 ‒1 42 3 4 39
Non-fatal, non-GI 2,622 ‒151 2,789 16 167 2,773
Non-fatal, GI 663 60 816 213 153 603
Acute myocardial infarction 1,138 185 1,136 183 ‒2 952
Fatal 13 2 13 2 0 11
Non-fatal 1,125 183 1,123 181 ‒2 942
n = number of events rounded to integer values
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Whether dabigatran can be considered cost-effective with
these ICERs depends on the threshold applied, which
means how much the health care system or society is will-
ing to pay for an additional QALY gained. As there is no
established threshold in Switzerland, we will briefly dis-
cuss what could be a plausible threshold by looking at three
reference values: 1) If we transfer the ICER threshold of
GBP 20,000 to GBP 30,000 per QALY [49] applied in the
English National Health Service to Switzerland by scal-
ing it on the gross domestic product (GDP) per capita in
2011 [50], we obtain a threshold of CHF 60,000 to CHF
90,000 per QALY. 2) If we apply the value proposed by the
WHO Commission on Macroeconomics and Health [51]
for highly cost-effective interventions (less than GDP per
capita), we obtain a threshold of CHF 72,000 per QALY in
2011 [50]. 3) The Swiss Federal Supreme Court uses a lim-
it of CHF 100,000 per life year in its judgment on the reim-
bursement of the drug Myozyme [52].
In the face of these thresholds between CHF 60,000 and
CHF 100,000 per QALY, dabigatran can be considered
cost-effective in Switzerland in all three dosage scenarios.
This result is confirmed by the four univariate SA and the
PSA. The SA on the TTR showed that cost-effectiveness of
dabigatran versus VKA is likely to be substantially better
in the real world than in a controlled trial population and
worse in a group of very well managed patients. In addition
Table 5: Number of events in the sequential dose model. The number of events represents the sum of clinical events of all 10,000 patients over their entire time in the
model. The difference to the number of events in the VKA arm is the result of relative effectiveness and lifetime of patients. As the sequential dose scenario is modelled on
a slightly different sub-population of the RE-LY trial, the comparison of the results of the sequential dose scenario with the other two scenarios should be limited to the
comparison of the ICER and should not include a comparison of the number of clinical events prevented.
Sequential dose dabigatran VKA
Events [n] ∆ to VKA [n] Events [n]
Ischemic stroke 4,079 ‒159 4,238
Fatal 1,537 8 1,529
Independent 1,389 ‒157 1,546
Moderate disability 706 42 664
Totally dependent 447 -52 499
Systemic embolism 488 -54 542
Fatal 2 0 2
Non-fatal 486 ‒54 540
Transient ischemic attack 1,261 ‒223 1,484
Intracranial haemorrhage and haemorrhagic stroke 465 ‒580 1,045
Fatal 194 ‒303 497
Independent 47 ‒43 90
Moderate disability 53 ‒50 103
Totally dependent 170 ‒185 355
Extra cranial haemorrhage 4,199 426 3,773
Fatal 51 6 45
Non-fatal, non-GI 3,254 195 3,059
Non-fatal, GI 894 226 668
Acute myocardial infarction 1,374 249 1,125
Fatal 15 3 12
Non-fatal 1,358 246 1,112
n = number of events rounded to integer values.
Table 6: Incremental costs and QALY in the whole patient population. As the sequential dose scenario is modelled on a slightly different subpopulation of the RE-LY trial,
the comparison of the results of the sequential dose scenario with the other two scenarios should be limited to the comparison of the ICER and should not include a
comparison of the number of clinical events prevented.
Dabigatran 110 mg Dabigatran 150 mg Sequential dose dabigatran
Incremental utility
Life years in the modela 111,001 111,382 120,399
Incremental life years 1,949 2,330 2,774
Incremental QALYc 1,848 2,433 2,846
Incremental costsb
Incremental drug cost 107,231,907 104,240,515 116,180,274
Incremental monitoring cost ‒38,766,790 ‒38,766,790 ‒42,509,345
Incremental event cost ‒4,549,378 ‒6,702,890 ‒6,273,658
Incremental follow-up cost ‒17,544,121 ‒35,187,222 ‒38,343,126
Incremental treatment discontinuation costd 17,057 22,880 19,481
Total incremental costs 46,388,675 23,606,493 29,073,626
Total incremental costs per life year in the model 418 212 241
ICERe 25,108 9,702 10,215
a Life years in the model are the sum of the residual lifetime of all 10,000 patients entering the model; b incremental cost is the difference in total medical costs of all 10,000
patients between the dabigatran arm and the VKA arm; c incremental QALY is the difference in total QALY experienced by all 10,000 patients between the dabigatran arm
and the VKA arm; d treatment discontinuation cost is the cost of one GP visit when the treatment is switched to acetyl salicylic acid without the occurrence of an adverse
event; e the incremental cost-effectiveness ratio (ICER) is the ratio between incremental costs and incremental QALY.
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compliance of patients on dabigatran may also be lower,
as periodic INR monitoring may enhance compliance. The
PSA showed that the ICER is particularly robust in the se-
quential scenario.
These results should be considered in light of the conser-
vative approach we took by making assumptions favour-
ing the cost-effectiveness of VKA rather than dabigatran.
The calculatory dose of Marcoumar®, for instance, is rather
low. We also tried to avoid an underestimation of the cost
of AMI, SE, and TIA, which are less effectively preven-
ted by dabigatran, by including the cost of the first year
after the event in the event cost calculation, instead of only
the first three months. On the contrary, we tended to un-
derestimate the costs of the clinical events that are more
effectively prevented by dabigatran. The cost of health
services used after an IS, HS and ICH are, for example, av-
eraged over a rather long residual lifetime, which reduces
the follow-up cost after these events. We also made a rather
conservative assumption regarding the length of GP visits
in the INR monitoring, since a 10-minute consultation per
INR test is the minimum to achieve a good INR adjustment
according to personal communication with GPs. We also
neglected the disutility of constant INR monitoring for pa-
tients.
The study has the following strengths. Firstly, it is based
on an elaborate model simulating the sequence of different
treatment options and a multitude of possible clinical
events. Secondly, we thoroughly adapted the costs of anti-
coagulation therapies and clinical events to the context of
the Swiss healthcare system. Thirdly, we followed a con-
servative approach in the calculation of treatment and event
costs, favouring VKA rather than dabigatran, which puts us
on the safe side in the interpretation of the results.
However, there are some limitations that need to be men-
tioned. Firstly, the generalisability of the results may be
limited since efficacy data mainly stemmed from patients
who met inclusion criteria for the RE-LY trial. A second
limitation is that QALY weights of single health events
cannot be adapted to the local context as they are simply
not available for Switzerland. Thirdly, in the absence of
Swiss data, we need to make several assumptions on the
frequency of services used and on the duration of therapies.
A fourth limitation is that the model does not include long-
term follow-up costs after AMI and SE, which does not
represent the Swiss standard of care. Fifth, the regular visits
for INR monitoring may not only induce medical costs but
may also help to maintain compliance. Thus compliance
could decrease when these regular visits are omitted after a
switch from VKA to dabigatran.
Conclusion
Dabigatran can be considered a cost-effective therapy op-
tion for the prevention of stroke among patients with atrial
fibrillation in Switzerland. The use of dabigatran is more
preferable the worse VKA patients are managed.
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Table 7: Univariate sensitivity analysis of the ICER in the three dabigatran dosage scenarios versus VKA. The univariate sensitivity analysis shows how the ICER (CHF/
QALY) changes when single model parameters are modified. The central column contains the ICERs of the base case analysis.
Time in INR target range
Dabigatran Self check (72%) Trial-like (64%) Real world (55%)
110 mg 38,608 25,108 6,291
150 mg 15,640 9,702 -812
Sequential 15,239 10,215 -417
CHADS2 at model entry
Dabigatran 0 1 2-6
110 mg 14,342 16,455 30,850
150 mg 10,636 10,034 9,520
Sequential 9,378 9,476 10,663
Price of daily dabigatran dose
Dabigatran CHF 3 CHF 4 CHF 5
110 mg 9,813 25,108 40,404
150 mg ‒1,598 9,702 21,002
Sequential ‒545 10,215 20,975
INR monitoring cost
Dabigatran CHF 175 CHF 511 CHF 735
110 mg 38,903 25,108 15,912
150 mg 20,176 9,702 2,719
Sequential 20,034 10,215 3,669
Discount rate
Dabigatran 0% 2% 4%
110 mg 22,538 25,108 27,861
150 mg 8,194 9,702 11,395
Sequential 8,639 10,215 11,968
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Figures (large format)
Figure 1
Simplified representation of Markov model.
Health states are modelled in 3-month cycles in which a patient may experience no event, a clinical event, or death. All clinical events induce
one-time treatment costs and a temporary loss of quality of life. IS, HS, and ICH may lead to permanent disability (moderate or total) causing
long-term follow-up costs and a permanent loss of quality of life. Disability levels can only get worse and never improve.
After a haemorrhagic event, 50% of the patients are assumed to discontinue treatment. Without any event, the time until treatment
discontinuation is modelled by a Weibull hazard function based on data from the RE-LY trial. After treatment discontinuation, 70% of patients on
dabigatran and 78% of patients on VKA are assumed to use ASA as a second line treatment.
AMI = acute myocardial infarction; ECH = extra-cranial haemorrhage; HS = hemorrhagic stroke; ICH = intracranial haemorrhage, IS = ischemic
stroke; MB = minor bleed; SE = systemic embolism; TIA = transient ischemic attack.
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Figure 2
Cost-effectiveness acceptability curves of dabigatran versus VKA in three dabigatran dosage scenarios.
The cost-effectiveness acceptability curve (CEAC) of dabigatran shows the probability of dabigatran to be the cost-effective treatment versus the
alternative VKA treatment at different ICER thresholds. The CEAC is generated on the basis of 10,000 PSA model runs. A point on the line can
be interpreted as the probability to correctly choose dabigatran as the cost-effective drug at a determinate ICER threshold. The dotted lines
indicate these probabilities at thresholds of CHF 25,000.‒, CHF 50,000.‒, and CHF 100,000.‒
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